Cabaletta Bio, Inc. 8K

Cabaletta Bio reported Q2 2026 results and outlined progress and timelines for registrational rese-cel autoimmune programs, expanded PC-free and outpatient dosing strategies, and strengthened manufacturing partnerships and liquidity to fund operations into mid-2027.

On August 13, 2026, Cabaletta Bio, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a comprehensive business update on its lead CAR T cell therapy rese-cel, confirming timelines for key registrational programs in autoimmune diseases, including mid‑2027 clinical data from the registrational RESET-Myositis cohort to support a planned second-half 2027 BLA submission (with juvenile myositis data intended to support a Priority Review Voucher), plans to initiate a single-arm registrational trial in approximately 25 patients with systemic sclerosis-associated interstitial lung disease in the fourth quarter of 2026, expansion of a preconditioning-free dosing approach and outpatient administration across multiple RESET trials, and enhancement of its manufacturing and supply chain through the addition of ElevateBio as a second CDMO alongside Lonza and implementation of a long-term automated commercial manufacturing partnership with Cellares, while indicating that its $225.1 million in cash, cash equivalents, and short-term investments is expected to fund operations into mid-2027.

Filing Facts

CIK

1759138

Ticker

-

Form

8K

Source Type

sec

Accession

0001759138-26-000038

Alert Tier

7